Da omalizumab clearence ved kliniske doser domineres af det reticuloendotheliale system (RES), er det usandsynligt, at den vil ændres af nedsat nyre - eller leverfunktion.
Because omalizumab clearance at clinical doses is dominated by the reticular endothelial system (RES) it is unlikely to be altered by renal or hepatic impairment.